Overview

Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)

Status:
Terminated
Trial end date:
2021-04-05
Target enrollment:
0
Participant gender:
All
Summary
This phase 2, double blind, placebo-controlled, randomized study is to assess the safety and efficacy of miricorilant (CORT118335) in patients with presumed Nonalcoholic Steatohepatitis (NASH).
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Corcept Therapeutics
Treatments:
Cortisone
Cortisone acetate
Criteria
Inclusion Criteria:

- Have a diagnosis of NASH based on a biopsy obtained within the last year OR

- Have a diagnosis of presumed NASH based on blood tests and scans

Exclusion Criteria:

- Have participated in another clinical trial within the last year and received active
treatment for NASH

- Have participated in another clinical trial for any other indication within the last 3
months

- Are pregnant or lactating women

- Have a BMI <18 kg/m2

- Have had liver transplantation or plan to have liver transplantation during the study

- Have type 1 diabetes or poorly controlled type 2 diabetes.